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We recently reported that oxidative stress elicited by chronic inflammation increases the mutation of mitochondrial DNA (mtDNA)
and possibly correlates with precancerous status. Since severe oxidative stress is elicited in the colorectal mucosa of individuals with
ulcerative colitis (UC), the possible occurrence of an mtDNA mutation in the inflammatory colorectal mucosa and colitic cancer was
investigated. Colorectal mucosal specimens were obtained from individuals with UC with and without colitic cancer and from control
subjects. The frequency of mtDNA mutations was higher in colorectal mucosal specimens from patients with UC than that from
control subjects. The levels of 8-hydroxy-20-deoxyguanosine, a DNA adduct by reactive oxygen species, were significantly higher in
UC than in control. Specimens from patients with colitic cancer contained a significantly higher number of mtDNA mutations. The
present observations suggest that the injury followed by the regeneration of colorectal mucosal cells associated with chronic
inflammation causes accumulation of mtDNA mutations. The increased instability of genes, including those on the mtDNA, is
consistent with the high and multicentric incidence of colorectal cancer in individuals with UC. Thus, analysis of mtDNA could provide
a new criterion for the therapeutic evaluation, and may be useful for the prediction of risk of carcinogenesis.
British Journal of Cancer (2005) 93, 331–337. doi:10.1038/sj.bjc.6602664 www.bjcancer.com
Published online 14 June 2005
& 2005 Cancer Research UK
Keywords: ulcerative colitis; mitochondrial DNA; carcinogenesis; inflammation; oxidative stress
                                               
Ulcerative colitis (UC) is an idiopathic disease characterised by
mucosal inflammation of the large bowel. Approximately 10
individuals per 100000 per year are diagnosed with UC in Western
countries (Russel and Stockbrugger, 1996). The number of patients
with UC has also been increasing in Japan, and the incidence is
now 53 per 100000. The aetiopathogenesis of UC remains
uncertain, but many factors may be involved in the initiation
and propagation of the chronic inflammatory response in UC
patients.
The relative risk of colorectal cancer development in UC
patients is 10 times greater than in the general population
(Brostrom et al, 1978; Kewenter et al, 1978; Prior et al, 1982;
Ekbom et al, 1990). The risk of developing cancer, or its precursor
lesion, dysplasia, increases exponentially with the duration of the
disease (Lashner et al, 1989). Risk factors affecting development
of colorectal cancer in UC are: greater extent of disease, duration
of disease (younger onset), and severity and time course of
inflammation (Collins et al, 1987; Sugita et al, 1990). The
histopathogenesis of UC-associated colorectal carcinogenesis is
widely believed to involve a step-wise progression from inflamed
and hyperplastic epithelia, to flat dysplasia, and finally adenocar-
cinoma (Riddell et al, 1983). This is often contrasted with the
adenoma-carcinoma sequence, thought to give rise to sporadic
colon cancer. The idea that cancer derives from a multistep
carcinogenesis process, entailing sequential alterations at the
molecular level that may underlie tissue-level changes, has gained
support from studies on many different cancers (Vogelstein et al,
1988; Sato et al, 1990; Presti et al, 1991). Similarly, UC-associated
cancer is presumed to arise from an accumulation of genetic
alterations in tumor suppressor genes, oncogenes, and genes
encoding DNA repair proteins, as well as an overall loss of genomic
stability. Comparisons of the molecular alteration profiles of
sporadic and UC-associated colorectal cancers have indicated
distinct differences. The timing and frequency of the molecular
genetic alterations in UC-associated cancers appear to be unique.
Mutation of the adenomatous polyposis coli (APC) gene is less
frequent (Greenwald et al, 1992; Kern et al, 1994), and that of the
K-ras gene is relatively less frequent (Fujimori et al, 1994) in UC-
associated cancer than sporadic adenoma and cancer. In contrast,
p53 is frequently mutated in the early stages of UC-associated
cancer; 33–67% in dysplasia and 83–95% in colitic cancer (Yin
et al, 1993; Brentnall et al, 1994). These distinctive molecular profiles
are presumed to result from different aetiological factors and
cellular environments that predispose an individual to the adenoma-
carcinoma sequence or to UC-associated carcinogenesis. The
mechanisms underlying these differences are yet to be elucidated.
It is well known that reactive oxygen species (ROS) in
inflammation are important inducers of both tissue injury and
DNA damage (Beckman and Ames, 1997). Since mitochondrial
DNA (mtDNA) lacks histones and related protective systems,
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smutations accumulate to a greater extent in it than in nuclear DNA
(Croteau and Bohr, 1997). The human mitochondrial genome
comprises a 16.5-kb circular double-stranded DNA molecule that
encodes 13 polypeptides of the respiratory chain, 22 transfer
RNAs, and two ribosomal RNAs required for protein synthesis.
Since expression of the entire mitochondrial genome is necessary
for the maintenance of mitochondrial functions, including electron
transport, small changes in the mtDNA sequence can result in
profound impairment of such functions, thereby enhancing
generation of free radicals, which in turn accelerates the rate of
DNA mutation. These highly reactive compounds can act as
initiators and/or promoters, cause DNA damage, activate procar-
cinogens, and inactivate antioncogenes (Trush and Kensler, 1991;
Feig et al, 1994). Therefore, the resulting injury to the
mitochondria underlying chronic inflammation may contribute
to the early stages of carcinogenesis. We recently reported that
oxidative stress associated with chronic hepatitis strongly en-
hanced the mutation of mtDNA both in cancerous and non-
cancerous regions of the liver (Nishikawa et al, 2001). Such
mutations of mtDNA are also detected in human cancers (Polyak
et al, 1998; Fliss et al, 2000). Interestingly, accumulation of mtDNA
mutations in cancerous tissue reflected the degree of malignancy.
We therefore hypothesised that the genetic instability in the
process of carcinogenesis results in the high rate of mtDNA
mutation, and sequenced the colorectal mucosal mtDNA in
individuals with UC. The increased instability of genes in mtDNA




The present study was performed in accordance with the Helsinki
Declaration of 1975 (1983 revision) and was approved by the ethics
committee of the Osaka City University Medical School. The entire
sequence was analysed from two controls (Control 1: 62-year-old
male; Control 2: 33-year-old male),and four patients with UC (UC-
Case 1: 37-year-old male with active colitis; UC-Case 2: 72-year-old
female with inactive colitis; UC-Case 3: 58-year-old female with
active colitis; and UC-Case 4: 48-year-old male with active colitis
complicated with dysplasia-associated lesion or mass, DALM). The
particular sequence of the displacement loop (D-loop) was studied
in 19 patients with UC without cancer (15 men and four women,
mean age 44.8 years, range 26–58), seven patients with UC-
associated cancer (three men and four women, mean age 42.6
years, range 33–66), and nine controls (six men and three women,
mean age 43.2 years, range 26–66). Samples of mucosal tissue in
inflammatory lesions were obtained either by biopsy or as surgical
specimens taken from controls suspected of having lower intestinal
disease, or from normal mucosa of patients with colorectal cancer
or adenoma, and patients with UC who underwent colonoscopy or
surgery. The procedure conformed to the approved Institutional
Review Board guidelines. Mucosal specimens included 19 samples
from 19 UC patients without cancer, four noncancerous and seven
cancerous samples from seven patients with colitic cancer, and
nine samples from nine control subjects without UC.
Polymerase chain reaction amplification
Fresh specimens were frozen, microdissected with a cryostat, and
digested with proteinase K (0.1mgml
 1) in the presence of 1%
SDS. DNA was extracted using phenol–chloroform, followed by
ethanol precipitation as described previously (Nishikawa et al,
2001). Each DNA sample (50ng) was subjected to amplification by
polymerase chain reaction (PCR) with overlapping sets of primers
to screen the entire mitochondrial genome. Polymerase chain
reaction (an initial incubation at 941C for 5min followed by 35
cycles of 941C for 30s, 551C for 30s, and 721C for 1min) was
performed in a final volume of 50ml with a GeneAmp PCR system
9600 (Perkin-Elmer, Oak Brook, IL, USA). Histopathological
diagnosis was confirmed by conventional haematoxylin and eosin
staining under light microscopy.
The generation of large PCR products excluded the possibility of
nuclear pseudogenes complicating the analysis (Parfait et al, 1998).
Furthermore, the primers were selected to avoid such complication
by analysis with cell lines devoid of mtDNA.
Sequence analysis
Aberrant PCR products were purified with a QIAquick PCR
purification kit (Qiagen, Chatswork, CA, USA) and sequenced with
an Applied Biosystems DNA sequencer (Perkin-Elmer, Oak Brook,
IL, USA) and a Dye Terminator Cycle Sequencing FS Ready
Reaction Kit (Applied Biosystems, Foster City, CA, USA). The
entire sequence of mtDNA was examined, by using the 17 sets of
specific primers (Polyak et al, 1998; Fliss et al, 2000; Nishikawa
et al, 2001), for two control (Control 1, Control 2) subjects and
three individuals with UC (UC-Case 1, UC-Case 2, UC-Case 3). The
entire sequence was also analysed for samples from noninflam-
matory, inflammatory and dysplastic regions in UC-Case 4. The
sequence of D-loop (nucleotide position 100–600) was examined
with the specific primers 50-TCACCCTATTAACCACTCACGGGA-30
(sense) and 50-TCACTGGAACGGGGATGCTTGC-30 (antisense) in
nine control subjects, 19 individuals with UC without cancer, and
seven colitic cancers. All mutations were confirmed by repeated
analysis of DNA extracted from the specimens.
Long PCR analysis to detect large deletions in mtDNA
DNA samples (500ng) were subjected to amplification by a long
PCR using an LA PCR
t Kit (TaKaRa Biomedicals, Kusatsu, Japan)
with primer 1 (50-GCGACATAGGGTGCTCCGGCTC-30) and pri-
mer 2 (50-GCGACATAGGGTGCTCCGGCTC-30). When any dele-
tions were present, products smaller than 16.5-kbp would be
generated by this primer set. The amplification profile involved an
initial incubation at 941C for 1min followed by 14 cycles of
981C for 20s, 681C for 20min, 16 cycles of 981C for 20s, 681C for
20minþ15s, and 721C for 1min in a final volume of 50ml with
a GeneAmp PCR system 9600 (Perkin-Elmer, Oak Brook, IL, USA).
The resulting products were electrophoresed and stained with
ethidium bromide.
Measurement of 8-hydroxy-20-deoxyguanosine levels in the
mucosal specimens
DNA extracted from mucosal specimens of nine control subjects
and 10 individuals with UC was suspended in 10mM Tris-HCl and
0.1mM EDTA (pH 8.0). In all, 5ml of 200mM sodium acetate buffer
(pH 4.8) and 5mg nuclease P1 (USB, Cleveland, OH, USA) were
added to 45ml DNA samples. After purging with a nitrogen steam,
the mixtures were incubated at 371C for 1h to digest the DNA to
nucleotides. Then, 5ml of 500mM Tris-HCl (pH 8.0), 10mM MgCl2,
and 0.6 units Escherichia coli alkaline phosphatase (Toyobo, Tokyo,
Japan) were added to the samples. After purging with a nitrogen
steam, the mixtures were incubated at 371C for 1h to hydrolyse
the nucleotides to nucleosides. The nucleoside samples were used
for the determination of 8-hydroxy-20-deoxyguanosine (8-OHdG)
by competitive ELISA kit (8-OHdG Check; Japan Institute for
the Control of Aging, Tokyo, Japan).
Statistical analysis
Statistical analyses of the results were made with Student’s t-test.
Spearmann’s correlation coefficient and regression analysis was
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sused for correlation analysis. P-values less than 0.05 were
considered significant.
RESULTS
The entire mitochondrial genomes of four UC specimens and two
control specimens were amplified by PCR and sequenced
manually. In UC-Case 4, the entire mitochondrial genomes from
three different specimens, noninflamed, inflamed, and DALM,
were analysed. The nuclear positions and changes of mtDNA
mutations found in Control 1, Control 2, UC-Case 1, UC-Case 2,
and UC-Case 3 are indicated in Table 1. When compared with the
mtDNA sequence stored in GenBank (accession no. #J01415) and
MITOMAP (http://www.mitomap.org/), the mtDNA sequence
obtained from the control specimens was found to contain 10
Table 1 mtDNA changes detected in the entire sequence of Control 1, 2 and UC-Case 1–3
Control 1 Control 2 UC-Case 1 UC-Case 2 UC-Case 3
Position Gene Change Position Gene Change Position Gene Change Position Gene Change Position Gene Change
248 D-loop del A 741 12SrRNA A-G 191 D-loop del A 500 D-loop del C 1074 12SrRNA ins C
2472 16SrRNA del A 2687 16SrRNA del C 200 D-loop A-C 514 D-loop del CA 1080 12SrRNA ins C
3969 ND1 C-T 6479 COI ins A 490 D-loop A-C 751 12SrRNA A-G 2036 12SrRNA ins C
4769 ND2 A-G 8639 ATPase6 T-C 1000 12SrRNA T-A 2686 16SrRNA G-C 3106 12SrRNA del C
6392 COI T-C 8850 ATPase6 A-G 1438 12SrRNA A-G 4386 Q T-C 4032 ND1 del CC
9053 ATPase6 G-A 8860 ATPase6 A-G 1486 12SrRNA C-G 4769 ND2 A-G 4919 ND2 ins T
10309 ND3 T-A 11720 ND4 G-A 3010 12SrRNA G-A 4958 ND2 A-G 5101 ND2 C-T
10590 ND4L T-G 15326 Cyt.b A-G 3285 L T-G 5895 COI ins C 6179 COI G-A
11947 ND4 A-C 3338 ND1 T-G 6455 COI C-T 6456 COI G-A
11955 ND4 A-C 4662 ND2 A-G 7337 COI G-A 7904 COII ins G
4768 ND2 T-G 7852 COII G-A 7917 COII ins G
4883 ND2 C-T 8861 ATPase6 C-G 8021 COII ins A
5178 ND2 C-T 10999 ND4 C-G 8483 ATPase8 A-T
5942 COI A-G 11084 ND4 A-G 8494 ATPase8 A-T
9860 COIII T-G 11102 ND4 ins G 8684 ATPase6 C-T
9883 COIII T-G 11771 ND4 C-G 8860 ATPase6 A-G
11853 ND4 C-T 11853 ND4 C-T 9540 COIII T-C
11247 ND4 C-G 12417 ND5 C-T 9572 COIII C-T
11457 ND4 C-G 12705 ND5 C-T 10027 ND3 ins G
11712 ND4 C-G 13586 ND5 C-T 10873 ND4 T-C
11719 ND4 G-A 13768 ND5 T-C 11335 ND4 T-C
11956 ND4 C-T 14364 ND6 G-A 12705 ND5 C-T
14570 ND6 C-G 14783 Cyt.b T-C 14783 Cyt.b T-C
16147 D-loop C-T 15043 Cyt.b G-A 15043 Cyt.b G-A
16245 D-loop C-T 16209 D-loop T-C 16184 D-loop C-T
16298 D-loop T-C
16319 D-loop G-A
16524 D-loop ins G
ND¼NADH (reduced nicotinamide adenine dinucleotide) dehydrogenase; CO¼cytochrome c oxidase; ATPase, ATP synthase; Cyt b, cytochrome b.F ,V ,L ,I ,Q ,M ,W ,A ,N ,
C, Y, S, D, K, G, R, H, E, T, and P¼tRNAs for phenylalanine, valine, leucine, isoleucine, glutamine, methionine, tryptophan, alanine, asparagine, cysteine, tyrosine, serine, aspartate,
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Figure 1 Location of mtDNA mutations in specimens of noninflammatory, inflammatory, and DALM from a patient with UC (UC-Case 3). Arrows
indicate the positions of mutations in mtDNA. Abbreviations: ND, NADH (reduced nicotinamide adenine dinucleotide) dehydrogenase; CO, cytochrome c
oxidase; ATPase, ATP synthase; Cyt b, cytochrome b; F, V, L, I, Q, M, W, A, N, C, Y, S, D, K, G, R, H, E, T, and P, tRNAs for phenylalanine, valine, leucine,
isoleucine, glutamine, methionine, tryptophan, alanine, asparagine, cysteine, tyrosine, serine, aspartate, lysine, glycine, arginine, histidine, glutamate, threonine,
and proline, respectively.
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sand eight mutations. This fact is consistent with a previous
observation that mtDNA in colorectal mucosa contains much
changes per individual (Polyak et al, 1998). The three UC speci-
mens contained 25 (UC-Case 1), 25 (UC-Case 2), and 28 (UC-Case
3) nucleotide changes. Consistent with previous observations
(Polyak et al, 1998; Fliss et al, 2000; Nishikawa et al, 2001), most
of the mtDNA mutations found in the present study were
homoplasmic.
Total mtDNA sequences could be compared in three different
samples in a patient with UC (UC-Case 4). The mtDNA sequence
obtained from the noninflammatory region (near/around the
inflammatory region) contained 41 mutations. Surprisingly, the
inflammatory and DALM specimens contained one and five
further mutations, respectively, in addition to 41 mutations found
in the noninflamed region in this patient (Figure 1).
To determine any large deletion profile in mtDNA, DNA
samples from Control 1, Control 2, and UC-Case 1, UC-Case 2,
UC-Case 3 and UC-Case 4 were subjected to a long PCR analysis
(Figure 2). However, no deletion was found in these six samples.
Furthermore, all of DNA samples used in the present study were
analysed with the same results.
As shown in Table 1 and Figure 1, the frequency of mtDNA
mutations was relatively high in the D-loop. We then compared the
position and the number of mutations in the D-loop region
(between nucleotides 100 and 600) among nine controls, 19
patients with UC without cancer, and seven patients with colitic
cancer (Table 2: position; Figure 3: number). For control speci-
mens, the median number of mutations in the D-loop was 0.67.









Figure 2 Long PCR analysis to detect large deletions in mtDNA. DNA
samples from Control 1 (lane 1), 2 (lane 2) and UC-Case 1–4 (lane 3–6,
respectively) were subjected to long PCR analysis as described in the text.
M; molecular marker.
Table 2 mtDNA sequence changes (nucleotide position 100–600) in control, UC without cancer, and UC with cancer










1 248, 548 1 248, 302, 482 1 199, 248, 302, 514, 527 1
194, 248, 302, 320,
514, 527, 530
2 302 2 499 2 194, 248, 527 2
199, 248, 302, 320,
514, 527
3 514 3 302, 482 3 191, 195, 199, 248,
302, 320, 514, 527
3
248, 302, 320, 514
4 — 4 199, 248, 302, 320,
514, 527
4 194, 248, 302, 320,
514, 527
4
191, 195, 199, 248,
302, 317, 320, 345,
456, 514, 527
5 — 5 302, 482 5
199, 248, 302, 514, 527
6 — 6 248, 302, 320, 514 6
199, 248, 302, 514, 527
7 302 7 — 7
194, 199, 248, 302,
320, 514, 527
8 302 8 514
9 — 9 248, 302
10 199, 248, 302, 514, 527
11 514
12 302, 482, 514
13 302, 499
14 194, 199, 302, 527
15 199, 248, 302, 514, 527
16 —
17 199, 248, 320, 514
18 194, 248, 527
19 248, 302, 482, 514
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scancer (P¼0.002 vs control), 5.50 for noncancerous specimens
(Po0.0001 vs control; P¼0.01 vs UC without cancer) and
cancerous specimens (Po0.0001 vs control; P¼0.0002 vs UC
without cancer) in UC with colitic cancer.
One patient was suffering the first onset, 18 were chronic and
relapsing type among patients with UC without cancer, and all
of the seven UC patients with colitic cancer were chronic and
relapsing type. There were four patients with left-sided colitis and
15 patients with total colitis type among UC patients without
cancer, and one patient with left-sided colitis and six patients with
total colitis type among UC patients with colitic cancer. Clinical
course and extent of the disease did not differ between patients
with UC and without colitic cancer. There was no significant
correlation between the number of mutations in the D-loop region
of UC colon not having cancer either with patient age (Figure 4A:
r
2¼0.09, P¼0.1572) or disease duration (Figure 4B; r
2¼0.006,
P¼0.7584). Furthermore, the data were irrespective of sex (data
not shown).
8-Hydroxy-20-deoxyguanosine, a DNA adduct by ROS, is known
as a parameter of oxidative stress. To evaluate increased oxidative
stress in UC, the levels of 8-OHdG in mucosa of controls and UC
without cancer were analysed. As shown in Table 3, the level of
8-OHdG in UC was significantly higher than that of controls.
DISCUSSION
Our data show that the number of mtDNA mutations in colorectal
mucosa from patients with UC tissue is substantially higher than
that previously reported with other types of cancer (Polyak et al,
1998; Fliss et al, 2000). The frequency and chronological process of
genetic mutations underlying sporadic cancer (adenoma-carcino-
ma sequence) and UC-associated carcinogenesis are different.
Even though the precise mechanism for such differences is not
known, increased ROS generation in the UC intestine (Oshitani
et al, 1993; Tomobuchi et al, 2001) is thought to be a major cause
of DNA damage in the inflammatory process (Seril et al, 2003), as
suggested in Table 3. Thus, the high incidence of mtDNA mutation
in the colorectal mucosa of UC patients indicates that mutation of
nuclear DNA is also enhanced in the colorectal epithelial cells of
UC patients during long-lasting inflammation. The observation
that most mtDNA mutations found in UC patients were homo-
plasmic in nature indicates that the mutated mtDNA had become
dominant in the colorectal mucosa of UC individuals. Mitochon-
drial DNA harboring certain types of mutations might result in the
generation of abnormal proteins, increasing the leakage of
electrons from the electron transport chain. The amounts of
endogenously produced free radicals might thus be increased in
cells with mutant mtDNA. The resulting increase in oxidative
stress could enhance the mutation of mtDNA and probably nuclear
DNA, thereby promoting the early stage of carcinogenesis, in









































Figure 3 Frequency distributions for the number of mutations in control,
UC without colitic cancer, noncancerous and cancerous mucosa of UC
with colitic cancer. The number of mutations in the D-loop (nucleotides
100–600) was compared among UC (without colitic cancer) colorectal
mucosa (n¼19) and specimens from noncancerous (n¼4) and cancerous
lesions (n¼7) of UC with colitic cancer, as well as tissues from controls
(n¼9).
12 Y = 5.948 – 0.069 X; r2 = 0.09
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Figure 4 Relationship between age and disease duration of patients with
UC without colitic cancer and the number of mtDNA mutations in the D-
loop region. (A) Relationship between the number of mtDNA mutations
in the D-loop region and patient age with UC and without colitic cancer.
(B) Relationship between the number of mtDNA mutations in the D-loop
region and disease duration.
Table 3 Levels of 8-OHdG in control (n¼9) and UC (n¼10)
Control UC
8-OHdG (ngmg
 1 DNA) 44.3710.7 132.8731.6 (Po0.001)
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slarge number of mtDNA copies, mutation of the mitochondrial
genome in the colorectal mucosa of UC individuals is indicative of
genomic instability that enhances carcinogenesis.
Each colorectal mucosal cell contains hundreds of mitochondria
and each mitochondrion contains B10 genomes (Wallace, 1992).
The mitochondria with mtDNA mutations in colorectal mucosal
cells proliferate selectively when such cells are fused with normal
cells (Polyak et al, 1998), possibly because certain mutant mtDNA
molecules exhibit a replicative advantage. The D-loop region of
mtDNA is important for both replication and expression of the
mitochondrial genome because it contains the leading-strand
origin and promotes replication and transcription, respectively
(Taanman, 1999). Thus, mutation in this region might affect the
affinity for trans-acting factors, thereby modulating the rate of
mtDNA replication. It has been well documented that mutation of
a gene occurs preferentially during its replication when single-
strand DNA appears. Analogously, mtDNA in the diverting
mitochondria also undergoes rapid replication and hence, its
susceptibility to mutagens and accumulation of mutated mtDNA
are increased compared to that under resting conditions. Thus, the
unusually high incidence of mtDNA mutations found in colorectal
mucosal cells from patients with UC seems to reflect the increased
mutation of nuclear DNA, a prerequisite for neoplastic transfor-
mation of cells.
Although activated leucocytes infiltrate inflammatory mucosa,
the number of such cells is fairly small compared with that of
mucosal epithelial cells. Moreover, the density of mitochondria in
mucosal epithelial cells is much higher than that in inflammatory
cells. Thus, the possible contribution of contaminated leucocytes
to the high incidence of mtDNA mutation observed in the
colorectal mucosa of UC patients is negligible. Furthermore,
mtDNA preparations from colorectal mucosal tissues in controls
and in individuals with UC were compared with those from paired
blood samples. No matched nucleotide changes except for a G-A
transition at nucleotide 263, a T-C transition at nucleotide 489,
C insertion between nucleotides 311 and 312, a A-G transition
at nucleotide 10398, a C-T transition at nucleotide 10400, and
aC -T transition at nucleotide 16223 were found in the blood
samples; suggesting that the mutations suggested in the present
study were not polymorphisms within the mitochondrial genome.
Large deletions of nucleotides have been described previously in
mtDNA from certain types of tumors (Yamamoto et al, 1992).
Despite extensive attempts to find deletions in mtDNA using
multiple primers for PCR analysis, we could not detect such
deletions in the colorectal mucosa from patients with UC. Thus,
colorectal epithelial cells with large deletions in their mtDNA
would have been eliminated, while cells without such deletions
preferentially underwent proliferation during the long-lasting
inflammation. It should be noted that the site of cells containing
mtDNA mutations is correlated or not correlated with their
position within the crypt. We tried to determine the site in several
specimens by microdissection. In any position of the crypt
analysed, we found the same mutations. Although it is difficult
to say that all of the cells in the crypt contain the same mutations,
the data in the results are thought to reveal the majority of the
mutations in the crypt.
Taylor et al (2003) reported that mtDNA mutations accumulated
in colonic crypt stem cells result in a significant biochemical defect
in their progeny. Consistent with this notion, the mtDNA
sequences obtained from the colorectal mucosa of control subjects
showed extensive mutation, although mtDNA in the livers from
normal subjects showed no sign of mutation (Nishikawa et al,
2001). These findings have important consequences for under-
standing the nature of intestinal tissues. Since the intestine harbors
large numbers of enterobacteria that constantly stimulate leuco-
cytes, the constitutive occurrence of inflammation in and around
the colorectal mucosa possibly increases the generation of free
radicals, thereby inducing the high rate of mtDNA mutation. It
should be noted that the mtDNA mutation spectrum in the present
study has predominance of transversions compared with other
types of cancers (MITOMAP (http://www.mitomap.org/)). Further-
more, mtDNA in UC patients contains some unique mutations
not found in other tissues. These facts possibly reflect either
oxygen damage to the colon or colon’s interaction with bulky
DNA adducts.
The frequency of mtDNA mutation is almost the same in
noninflammatory and inflammatory regions. The fact that patient
age and disease duration did not significantly correlate with the
number of mtDNA mutations indicates that mtDNA mutations in
the colitic mucosa do not simply reflect duration but may well
reflect long-term inflammatory activity of patients with UC. Most
of the identified mutations in mtDNA were homoplasmic because
of the replicative advantage of certain mutant mtDNA molecules
undergoing repeated destruction in chronic inflammation, even
though enterocytes contain thousands of mitochondrial genomes.
Our data suggest that mtDNA mutations accumulate during the
neoplastic transformation of enterocytes.
The high incidence of mtDNA mutation in colorectal tissues of
individuals with UC suggests that the rate of DNA mutation is
enhanced in their mucosal cells by oxidative stress caused by
chronic inflammation and, hence, malignant transformation
occurs more easily than in normal subjects.
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